Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Non-Small Cell Lung Cancer Metastatic 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Pemetrexed 2Nivolumab 2Cisplatin 2Carboplatin 2tepotinib 1pembrolizumab 1patritumab deruxtecan 1lazertinib 1durvalumab 1atezolizumab 1Taxes 1Radiotherapy 1Radiosurgery 1Ipilimumab 1BO-112 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer Metastatic × patritumab deruxtecan × Thoracic × Clear all
NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Active not recruiting
277 enrolled 16 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡